- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | AZ secures capacity for one billion coronavirus vaccine doses | ||
| Fr | EMA starts review of MorphoSys' tafasitamab for lymphoma | ||
| Fr | Gilead, Galapagos dip on mixed ulcerative colitis data | ||
| Do | Roche makes protein degradation play with $135m Vividion deal | ||
| Do | Octapharma cleared to start phase 3 trial of Octagam in COVID-19 | ||
| Do | UK government expands coronavirus testing criteria | ||
| Do | Recruiting for a COVID-19 clinical trial? | ||
| Do | Medical affairs - a strategic function for scientific engagement | ||
| Mi | FDA gives Roche's Tecentriq green light for first-line NSCLC | ||
| Mi | Trailing Clovis, AstraZeneca gets FDA approval for Lynparza in prostate cancer | ||
| Mi | Biopharma body welcomes EU-UK free trade agreement docs | ||
| Mi | The far-reaching impact of the COVID-19 pandemic on clinical trials | ||
| Di | Moderna's coronavirus vaccine hits first objectives | ||
| Di | Focusing on patient centricity to build trust in pharma | ||
| Di | Novartis claims EU approval for SMA gene therapy Zolgensma | ||
| Di | FDA clears phase 2 COVID-19 trial of ViralClear's merimepodib | ||
| 18.05. | New truths and realities in these strange times | ||
| 18.05. | After the watershed: the dos and don'ts of digital KPIs in a post-pandemic world | ||
| 18.05. | UK pledges £131m for a "rapid deployment facility" to make coronavirus vaccines | ||
| 18.05. | AZ, Daiichi Sankyo's Enhertu fast-tracked in US for NSCLC | ||
| 18.05. | ViiV takes on Gilead's PReP dominance with HIV injectable data | ||
| 18.05. | Taking the 'free' out of 'freelance' and bringing it in-house | ||
| 15.05. | BMS sets out its first-line NSCLC stall at ASCO | ||
| 15.05. | Sanofi in the firing line over 'US-first' COVID-19 vaccine plan | ||
| 15.05. | Merck's Keytruda hits the mark in triple negative breast cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
